Analytical Data
-
基因名
HLA-A*02:01&B2M&KRAS G12V(KLVVVGAVGV) Monomer
- Application
-
别名
HLA-A*0201 & B2M & KRASG12V (KLVVVGAVGV)
-
种属
Human
-
表达系统
HEK293
-
标签
C-Avi;C-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
AAA59606.1 (G25-I308)&P61769
-
表达区间
AAA59606.1 (G25-I308)&P61769 (I21-M119)&KLVVVGAVGV
-
分子量
40-43 kDa and 10 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The HLA-A*02:01/B2M/KRAS G12V monomeric recombinant protein is of significant interest in the context of cancer immunology and therapeutic vaccine development. The KRAS protein, particularly the G12V mutation, is commonly associated with various aggressive cancers, including pancreatic, colorectal, and lung cancers. This mutation alters the normal function of the KRAS protein, leading to unregulated cellular proliferation and survival. HLA-A*02:01 is one of the most prevalent human leukocyte antigen (HLA) class I molecules that presents peptide antigens to CD8+ T cells, critically influencing immune recognition of tumors. The combination of HLA-A*02:01 and the KRAS G12V peptide (KLVVVGAVGV) creates a valuable tool for studying immune responses and developing targeted therapies, as it can help in identifying potential T cell responses against KRAS-mutant tumors. Moreover, the recombinant expression of this complex facilitates the study of T cell receptor (TCR) specificity, the design of peptide-based vaccines, and the exploration of novel immunotherapeutic strategies. Understanding the interactions between T cells, HLA molecules, and mutant peptides can ultimately lead to breakthroughs in personalized cancer treatment, aiming to enhance the efficacy and specificity of immune responses against tumors harboring KRAS mutations.
